论文部分内容阅读
溶栓疗法是急性心肌梗塞(AMI)的现代常规治疗方法。链激酶是价廉的溶栓药物,应用最为广泛。链激酶是异种蛋白,具有抗原性。据报告,链激酶过敏反应发生率为1.7%～18%。本文探讨 AMI 患者在给予链激酶治疗后的抗体反应,以便更可靠地测知链激酶治疗的安全性。病人及方法 48例 AMI 患者,男38例、女10例,年龄42～80岁。其中22例仅在治疗前
Thrombolytic therapy is a modern, conventional therapy for acute myocardial infarction (AMI). Streptokinase is a cheap thrombolytic drugs, the most widely used. Streptokinase is a heterologous protein that is antigenic. According to the report, the incidence of streptokinase anaphylaxis is 1.7% ~ 18%. This article explores the antibody response of patients with AMI after administration of streptokinase in order to more reliably measure the safety of streptokinase therapy. Patients and Methods 48 AMI patients, 38 males and 10 females, aged 42 to 80 years. Of these, 22 were just before treatment